Gene · 9682
Papers1,858
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 1,858
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cantharidin Inhibits Proliferation of Liver Cancer by Inducing DNA Damage via KDM4A-Dependent Histone H3K36 Demethylation. | Evid Based Complement Alternat Med | 2022 | 35860003 | PubTator, text mining | PubMed |
| Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. | Sci Transl Med | 2022 | 35857643 | PubTator, text mining | PubMed |
| Exploring links between 2-oxoglutarate-dependent oxygenases and Alzheimer's disease. | Alzheimers Dement | 2022 | 35852137 | PubTator, text mining | PubMed |
| Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4. | Front Oncol | 2022 | 35847900 | PubTator, text mining | PubMed |
| Retraction notice to "KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/β-catenin signaling pathway" [Life Sci. 262 (2020) 118508]. | Life Sci | 2022 | 35840414 | PubTator, text mining | PubMed |
| Recent Advances with KDM4 Inhibitors and Potential Applications. | J Med Chem | 2022 | 35838529 | PubTator, text mining | PubMed |
| Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma. | Front Oncol | 2022 | 35837104 | PubTator, text mining | PubMed |
| KDM4 inhibitor SD49-7 attenuates leukemia stem cell via KDM4A/MDM2/p21CIP1 axis. | Theranostics | 2022 | 35836814 | PubTator, text mining | PubMed |
| Investigation of the Mechanism of hsa_circ_000 1429 Adsorbed miR-205 to Regulate KDM4A and Promote Breast Cancer Metastasis. | Contrast Media Mol Imaging | 2022 | 35833065 | PubTator, text mining | PubMed |
| N6-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming. | Theranostics | 2022 | 35832094 | PubTator, text mining | PubMed |
| Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review. | Nutrients | 2022 | 35807785 | PubTator, text mining | PubMed |
| Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. | Front Oncol | 2022 | 35785151 | PubTator, text mining | PubMed |
| Crosstalk Between Histone and m6A Modifications and Emerging Roles of m6A RNA Methylation. | Front Genet | 2022 | 35783260 | PubTator, text mining | PubMed |
| Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. | Front Oncol | 2022 | 35774123 | PubTator, text mining | PubMed |
| Risk coefficient model of necroptosis-related lncRNA in predicting the prognosis of patients with lung adenocarcinoma. | Sci Rep | 2022 | 35768485 | PubTator, text mining | PubMed |
| The Chromatin Landscape Channels DNA Double-Strand Breaks to Distinct Repair Pathways. | Front Cell Dev Biol | 2022 | 35757003 | PubTator, text mining | PubMed |
| Clioquinol as an inhibitor of JmjC-histone demethylase exhibits common and unique histone methylome and transcriptome between clioquinol and hypoxia. | iScience | 2022 | 35754713 | PubTator, text mining | PubMed |
| Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers. | Cancers (Basel) | 2022 | 35740507 | PubTator, text mining | PubMed |
| 2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies. | Biomedicines | 2022 | 35740380 | PubTator, text mining | PubMed |
| Correction: JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway. | J Exp Clin Cancer Res | 2022 | 35715839 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9682/papers?page=20